Interferon signaling restrains renal cell carcinoma heterogeneity.
CGAS
CNV
cancer stem cells
cancer/immunity coevolution
immunoevasion
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
14
08
2023
accepted:
17
08
2023
medline:
23
10
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
Type I interferon (IFN) is central to cancer surveillance as it mediates both direct and immune-mediated oncosuppressive effects. A recent study by Perelli et al. suggests that the ability of renal cancer cells to tolerate complex karyotypic alterations elicited by chromosomal instability (CIN), and ultimately acquire full metastatic potential, is also negatively regulated by IFN signaling.
Identifiants
pubmed: 37658022
pii: S2405-8033(23)00168-1
doi: 10.1016/j.trecan.2023.08.008
pii:
doi:
Substances chimiques
Nucleotidyltransferases
EC 2.7.7.-
Interferon Type I
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-873Subventions
Organisme : NCI NIH HHS
ID : R01 CA271915
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA274291
Pays : United States
Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.H. and J.F. are full-time employees of Sotio a.s. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options.